title: Long-term efficacy and toxicity of the FEC100 regimen.
abstract: Adjuvant chemotherapy has been shown to be beneficial in patients with breast cancer, and anthracycline-containing regimens are more effective than non-anthracycline-containing ones. The French Adjuvant Study Group (FASG) compared FEC100 and FEC50 (fluorouracil [5-FU]/epirubicin [Ellence]/cyclophosphamide [Cytoxan, Neosar]) in patients with node-positive breast cancer, with an endpoint of overall survival. After a median follow-up of 10 years, the benefit/risk ratio of the FEC100 regimen in patients with positive axillary nodes is strongly positive. Furthermore, a medicoeconomic study showed that the cost per year of life saved was very low--approximately 1000 Euros.
authors.affiliation: Breast Cancer Department, Centre Oscar Lambret, Lille, France. j-bonneterre@o-lambret.fr
authors.forename: Jacques M
authors.initials: JM
authors.lastname: Bonneterre
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000473:pathology / Q000601:surgery; D003362:Cost-Benefit Analysis; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000139:chemically induced; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil